Last reviewed · How we verify
Anti-angiogenesis
Inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF)
Inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF) Used for Treatment of various cancers.
At a glance
| Generic name | Anti-angiogenesis |
|---|---|
| Sponsor | Amgen |
| Drug class | Anti-angiogenesis agent |
| Target | VEGF |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
Anti-angiogenesis drugs like this one work by blocking the action of VEGF, a protein that promotes the formation of new blood vessels. This can help slow the growth of tumors and reduce the risk of metastasis.
Approved indications
- Treatment of various cancers
Common side effects
- Fatigue
- Headache
- Nausea
Key clinical trials
- SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma (PHASE2)
- Comparing the Combination of Sullumab and Fruquintinib in Postoperative Adjuvant Therapy for High Recurrence Risk Non Transparent Renal Cell Carcinoma (PHASE2)
- Safety and Efficacy of Yiwoxidan Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Are Intolerant to TKI Treatment: a Prospective, Single Arm, Phase II Clinical Study (PHASE2)
- Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma. (PHASE1, PHASE2)
- Predictive Impact of MMP2 and MMP9 Levels for Patients With Metastatic Kidney Cancer Treated With Anti-angiogenic Agents (NA)
- Combination of High and Low-Dose Radiotherapy With Immune Therapy and TKI in Advanced Colorectal Cancer: A Phase II Study (PHASE2)
- Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma (PHASE2)
- Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti-angiogenesis CI brief — competitive landscape report
- Anti-angiogenesis updates RSS · CI watch RSS
- Amgen portfolio CI